Albeit rare, ERBB2ΔEx16 was implicated mostly in resistance to anti-HER2 agents in HER2-positive breast tumors and osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) (5, 12, 16, 18). Here, EGFR is linked to non-small cell lung carcinoma.